Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04919018 · ClinicalTrials.gov registry record

Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies

A clinical trial, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
159
Enrollment target

NCT04919018 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 159 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04919018 has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
159 participants
Enrollment target

Study Summary

Though common, morbidities related to upper airway disease in primary ciliary dyskinesia (PCD) and primary immunodeficiencies (PID) have not been fully characterized. These conditions can be difficult to distinguish due to their overlapping phenotypes. The sinonasal and middle ear features are often identified as most problematic by patients and their families, and optimal, highly effective treatment regimens have not been established. The main objective of this project is to characterize and compare the upper airway phenotypes in individuals with confirmed diagnosis of PCD and PID, and to collect critical data to inform the design of future clinical trials of treatment of the upper airway diseases. The investigators anticipate that these investigations will discern the clinical, anatomical, and pathophysiological phenotypes of paranasal sinus disease in PCD and PID, identifying disease endpoints and biomarkers that differentiate these two overlapping disorders. Findings from these studies will also enhance our understanding of middle ear disease and associated hearing loss in a cross-sectional cohort of patients with PCD and PID. Ultimately, the long-term goal of our Consortium is to elucidate underlying phenotypes and genotypes of these diseases, potentially leading to novel therapeutics that will improve the lives of affected individuals. Given the COVID pandemic, certain procedures will have the option to be converted to telehealth visits to ensure compliance with local guidelines and participant safety.

Trial Details

FieldValue
Enrollment Target 159 participants
Start Date 2021-06-09
Est. Completion 2025-07-23

What the Registry Record Tells You About NCT04919018

The ClinicalTrials.gov registry entry for NCT04919018 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04919018 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04919018 about?

NCT04919018 is a clinical study titled "Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies". Though common, morbidities related to upper airway disease in primary ciliary dyskinesia (PCD) and primary immunodeficiencies (PID) have not been fully characterized. These conditions can be difficult to distinguish due to their overlapping phenotypes. The sinonasal and middle ear features are often...

What is the current status of trial NCT04919018?

This trial is currently completed. The enrollment target is 159 participants. The study started on 2021-06-09. Estimated completion is 2025-07-23.

Who is sponsoring clinical trial NCT04919018?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.